Amgen (AMGN) PT Raised to $192 at RBC Capital on Increased Enbrel Sales
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay raised the price target on Amgen (NASDAQ: AMGN) to $192.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
